DV
Dividend Vision

CRDF — Cardiff Oncology Inc

Cardiff Oncology Inc (CRDF)

Total return is -99.9% over the past 22 years, 1060.5 points behind SPY at 960.6%. Its deepest 1-year drawdown was 74.8%.

Cardiff Oncology is a clinical-stage biotechnology company developing novel cancer therapies, with its lead candidate Onvansertib, an oral polo-like kinase 1 inhibitor, currently in clinical trials for treating RAS-mutated colorectal cancer and other solid tumors including pancreatic and lung cancers. The company does not currently distribute dividends. Cardiff Oncology appeals to investors with high risk tolerance seeking exposure to early-stage oncology drug development, though the company remains unprofitable and dependent on clinical trial outcomes.

CRDF key facts

Asset type
Stock
Asset class
Equity
Inception date
07/27/2004
Last close
$0.96
Market cap
$68,343,416
Average volume
481200.0
Payment date
02/20/2019
Beta
1.436
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.67